PG

BEHAVIORAL2 trials

Sponsors

Jules Bordet Institute, University of Padova

Conditions

Non-metastatic Muscle Invasive Bladder CancerShoulder Pain

Phase 2

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)

CompletedNCT03674424

Jules Bordet InstituteNon-metastatic Muscle Invasive Bladder Cancer

Start: 2018-06-01End: 2025-01-30Updated: 2025-02-26

Unknown Phase

Digital Therapy in Shoulder Rehabilitation.

CompletedNCT05230056

University of PadovaShoulder Pain

Start: 2021-01-01End: 2021-11-30Updated: 2022-02-08

Related Papers

Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004).

2026-01-13

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial

Journal for ImmunoTherapy of Cancer2025-05-012 citations

Avelumab (A) as neoadjuvant therapy in patients (pts) with muscle-invasive urothelial carcinoma (MIUC): Survival data of AURA trial, Oncodistinct 004.

Journal of Clinical Oncology2024-06-018 citations

Effectiveness and therapeutic compliance of digital therapy in shoulder rehabilitation: a randomized controlled trial.

2023-07-0811 citations

Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial.

Journal of Clinical Oncology2022-06-0119 citations

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).

2021-12-0216 citations